linjc16/ctgov huggingface dataset:
Follow up of Patients With Aortic Aneurysm by Dosage of Circulant Endothelial Progenitor Cells

Study Overview
=================
Brief Summary
-----------------
The study aims to investigate the existence of a reliable correlation between the progression of aortic diameters and blood levels of circulant endothelial progenitor cells CD34+ in patients with not surgical aortic aneurysms.

Official Title
-----------------
Follow up of Patients With Aortic Aneurysm by Dosage of Circulant Endothelial Progenitor Cells

Conditions
-----------------
Thoracic or Abdominal Aortic Aneurysm With no Indication for Surgical Treatment

Intervention / Treatment
-----------------
* Biological: blood taking


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients aged 18 or more. Patients diagnosed with a thoracic or abdominal aortic aneurysm with no indication for surgical treatment (diameters > 30 mm but < 50 mm). Patients accepting to sign a specific informed consent. Exclusion Criteria: Unstable coronary artery disease. Congenital heart disease. Any evolving infectious syndrome or viral infection (HIV, HBV or HCV). Any chronic inflammatory or autoimmune disease. Prior administration of G-CSF; EPO; GM-CSF. Liver failure. Prior oncologic disease or ongoing cancer with a life expectancy < 1 year. Dementia. Pregnancy. Patients aged < 18.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: thoracic or abdominal aortic aneurysm<br> | Biological: blood taking<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| progenitor cells CD34+ blood levels |  | At diagnosis of aneurysm | 
| progenitor cells CD34+ blood levels |  | 6 month after disgnosis | 
| progenitor cells CD34+ blood levels |  | 12 month after diagnosis | 
| progenitor cells CD34+ blood levels |  | 18 month after diagnosis | 
| progenitor cells CD34+ blood levels |  | 24 month after diagnosis |
Efficacy of Inhaled Nitroglycerin in Moderate to Critically Ill COVID-19 Patients

Study Overview
=================
Brief Summary
-----------------
In current analysis moderate to severely ill Covid-19 infected patients will be nebulized with nitroglycerin, and they will be compared with the standard nebulization

Official Title
-----------------
Efficacy of Inhaled Nitroglycerin in Moderate to Severe Cases of COVID-19 Patients

Conditions
-----------------
Corona Virus Infection

Intervention / Treatment
-----------------
* Drug: Nitroglycerin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosed admitted cases of Covid-19 degree of illness should be moderate to severe both male and female every age group Exclusion Criteria: allergic to nitroglycerin sudden drop in blood pressure not given consent
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Nitroglycerin solution<br> | Drug: Nitroglycerin<br>* 2 mg/ml solution of nitroglycerin used for nebulization four hourly<br>|
| No Intervention: standard solution<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ratio of partial pressure of oxygen in arterial blood to fraction of inhaled oxygen |  | 5-7 days | 
| Oxygen demand |  | 5-7 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Duration of hospital stay |  | 15 days |
Circuit-Based Deep Brain Stimulation for Parkinson's Disease; Udall Project 1 Aim 2 and 3

Study Overview
=================
Brief Summary
-----------------
This study will test the hypothesis that deep brain stimulation (DBS) targeting specific changes in oscillatory activity at the site of stimulation will prove superior to continuous isochronal DBS thus providing the rationale for development and optimization of closed loop paradigms and determine whether the optimal closed-loop biomarker varies across subcortical targets, is task dependent, or serves to re-establish a default network that removes an underlying disruptive physiological state leading to greater improvement in motor signs and task performance.

Official Title
-----------------
Circuit-Based Deep Brain Stimulation for Parkinson's Disease; Udall Project 1 Aim 2 and 3

Conditions
-----------------
Parkinson Disease

Intervention / Treatment
-----------------
* Device: Stimulation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of idiopathic PD DBS surgery or IPG battery replacement at UMN is planned as part of routine clinical care. Exclusion Criteria: Other significant neurological disorder History of dementia Prior history of stereotactic neurosurgery Patients with post-operative complications or adverse effects (e.g. ON stimulation dystonias) that affect patient safety or confound the experiment will be excluded from further study Pregnant women

Ages Eligible for Study
-----------------
Minimum Age: 22 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Stimulation<br>Traditional deep brain stimulation | Device: Stimulation<br>* Traditional deep brain stimulation<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Measure local field potential (LFP) changes in subthalamic nucleus (STN) and globus pallidus (GP) in OFF and ON states of stimulation and medication | Clinical ratings scales (MDS-UPDRS) | 2 days |
Dynamics of Stroke Volume and Cardiac Output During Parabolic Flight, and Its Relationship to Intravascular Volume

Study Overview
=================
Brief Summary
-----------------
To understand the cardiovascular reactions of the human body to changing conditions of gravity is an important aim of space science. In this context, cardiac output (CO) is a key value to estimate the human cardiovascular system. The main objective of this experiment is to determine the effects of parabolic flight on intravascular volume, and how these changes modulate the complex haemodynamics induced by the parabolas.

Conditions
-----------------
Healthy Volunteers

Intervention / Treatment
-----------------
* Other: Parabolic flight
* Other: plasma volume measurements


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: healthy volunteers (men or women), aged from 18 to 55, affiliated to a Social Security system, who accept to take part in the study, who have given their written stated consent, who already participated in parabolic flights (even in the same campaign) All subjects will pass a medical examination similar to a standard aviation medical examination for private pilot aptitude. There will be no additional test performed for subject selection Exclusion Criteria: person who took part in a previous biomedical research protocol, of which exclusion period is not terminated, pregnant women

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Plasma volume measurements<br> | Other: Parabolic flight<br> <br> Other: plasma volume measurements<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| haemoglobin concentration |  | baseline |
Spinal Anesthesia Magnesium Infusion

Study Overview
=================
Brief Summary
-----------------
The aim of this study was to investigate the effect of i.v. infusion of magnesium sulphate during spinal anesthesia on duration of spinal block and postoperative pain.

Official Title
-----------------
The Effect of Intravenous Magnesium Sulfate Infusion on Sensory Spinal Block and Postoperative Pain Score in Abdominal Hysterectomy

Conditions
-----------------
Operation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ASA physical status I and II, aged between 18 and 65 female patients undergoing abdominal hysterectomy Exclusion Criteria: severe cardiovascular, renal and hepatic dysfunction, neuromuscular diseases, using calcium channel blockers, and inappropriate for spinal anesthesia.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| pain scores |  | 6 mo | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| sensory block |  | 6 mo |
Detection and Pathogenesis of Novel Protein F

Study Overview
=================
Brief Summary
-----------------
From December 6, 2019 to March 23, 2020, the research group of Qingkun Fan found a novel protein(temporarily named protein F) in heparin anticoagulant plasma of three patients with heart disease. One patient was diagnosed with multiple myeloma.However, protein F cannot be detected by serum protein electrophoresis. Preliminary studies have shown that this novel protein F have an obvious absorption peak at about 600nm. Placed at 2-8 degrees for 7 days, protein F will be isolated from heparin plasma. To the naked eye, protein F appear to be transparent jelly between the red blood cells and the plasma. The specific protein F, how it is produced, how it causes disease are still unknown. This study will explore how to detect protein F and how it is produced.

Detailed Description
-----------------
Protein F screening was performed on anticoagulant blood plasma with heparin Lithium or blood serum by in-house turbidimetric method in Automatic biochemical analyzer. All patients were followed-up for 3 years by telephones, routine appointment out-patient clinic or returning visit.

Official Title
-----------------
Detection and Pathogenesis of Novel Protein F

Conditions
-----------------
Cardiac Disease, Multiple Myeloma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Testing total protein and albumin Testing routine blood test Exclusion Criteria: high triglycerides (TG>5.00 mmol/L) hyperbilirubinemia (TBIL>170 mmol/L) fat emulsion used in past 3 days patients with hemolytic disease pregnant and lactating women

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Concentration of plasma protein F content | the protein F content was measured by turbidimetric assay in automatic biochemical analyzer | six month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Participants with Multiple myeloma | Develop or be diagnosed with multiple myeloma | 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
diagnosis, protein, cardiac disease, multiple myeloma, globulin
Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for Stroke

Study Overview
=================
Brief Summary
-----------------
This trial will study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of Stroke

Detailed Description
-----------------
This patient funded trial aims to study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord derived mesenchymal stem cells (UC-MSCs) for the treatment of Stroke. Patients will receive a single intravenous infusion of UC-MSCs. The total dose will be 100 million cells. Patients will be evaluated within one month pre treatment and at 1, 6, 12, 24, 36, and 48 months post treatment for safety and efficacy. For patients with more severe disease an autologous Effector cells (activated lymphocytes) treatment will be utilized created from the patient's own cells obtained by apheresis.

Official Title
-----------------
Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Stroke

Conditions
-----------------
Stroke

Intervention / Treatment
-----------------
* Biological: AlloRx


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of Stroke Understanding and willingness to sign a written informed consent document Exclusion Criteria: Active infection Active cancer Chronic multisystem organ failure Pregnancy Clinically significant Abnormalities on pre-treatment laboratory evaluation Medical condition that would (based on the opinion of the investigator) compromise patient's safety. Continued drug abuse Pre-menopausal women not using contraception Previous organ transplant Hypersensitivity to sulfur
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Treatment Group (AlloRx)<br>Single intravenous infusion of 100 million cells | Biological: AlloRx<br>* cultured allogeneic adult umbilical cord derived mesenchymal stem cells<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety (adverse events) | Clinical monitoring of possible adverse events or complications | Four year follow-up | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Stroke, stem cell treatment
Early Gastric Decompression During Advanced Cardiopulmonary Resuscitation (EGD_ACLS)

Study Overview
=================
Brief Summary
-----------------
This study aimed to identify the effect of early gastric decompression on the improvement of circulation in arrest patients during cardiopulmonary resuscitation at the clinical setting of emergency department.

Detailed Description
-----------------
Subjects and setting : adult sudden cardiac arrest patients in out of hospital, and transported to emergency department for advanced resuscitation treatment Interventions: first step, establish the advanced airway, after then insertion the naso (or oro)-gastric tube during CPR Data collection: live observation and review the automatically recoding data Missing or failed data should be collected and descriped Study period and sample size: numbers of participants necessary to identify the effect of interventions; 12 months or lesser were anticipated Analysis: All collected data can be analysed by Statistical programs

Official Title
-----------------
The Clinical Study for the Identifying the Effect of Early Gastric Decompression on Improvement of Circulation During Advanced Cardiopulmonary Resuscitation

Conditions
-----------------
Out-of-Hospital Cardiac Arrest

Intervention / Treatment
-----------------
* Procedure: Gastric decompression


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Out of cardiac arrest patients who was transported to the emergency department for advanced resuscitation care Exclusion Criteria: Do not attempted Inevitable death cofirmed at Emergency department Early recovery of spontaneous circulation before the intervention or sufficient collections of outcome data data loss others

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: EGDgroup<br>Intervention (gastric decompression by naso(oro)-gastric tube insertion) was performed | Procedure: Gastric decompression<br>* Insertion the Naso(Oro)-gastric tube for early gastric decompression during CPR<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evidence of improvement of circulatuion during CPR by evalution of increased end tidal CO2 (ETCO2) durig CPR |  | Within 10-20 min of CPR | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
cardiopulmonary resuscitation, Gastric emptying
Efficacy of Ciclesonide vs Fixed Combination of Fluticasone Propionate/Salmeterol vs Placebo in Patients With Mild Persistent Asthma (12 to 75 y) (BY9010/M1-132)

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to compare the efficacy of ciclesonide versus fixed combination of fluticasone propionate/salmeterol versus placebo, on long-term asthma control in patients with mild persistent asthma. The study duration consists of a baseline period (2 weeks) and a treatment period (12 months). The study will provide further data on safety and tolerability of ciclesonide.

Official Title
-----------------
Efficacy of Ciclesonide and of a Fixed Combination With Fluticasone Propionate and Salmeterol Versus Placebo on Long-term Asthma Control

Conditions
-----------------
Asthma

Intervention / Treatment
-----------------
* Drug: Ciclesonide


Participation Criteria
=================
Eligibility Criteria
-----------------
Main Inclusion Criteria: Clinical diagnosis of mild persistent asthma Pre-treatment with SABAs only FEV1 ≥80% predicted Good health with the exception of asthma Main Exclusion Criteria: Concomitant severe diseases or diseases which are contraindications for the use of inhaled steroids COPD (chronic bronchitis or emphysema) and/or other relevant lung diseases causing alternating impairment in pulmonary function Pregnancy Intention to become pregnant during the course of the study Breast feeding Lack of safe contraception Current smokers ≥10 pack-years and ex-smokers with ≥10 pack-years

Ages Eligible for Study
-----------------
Minimum Age: 12 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Ciclesonide|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| time until the first severe asthma exacerbation occurs |  |  | 
| number of poorly controlled asthma days. |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| percentage of days with asthma control |  |  | 
| percentage of days with asthma symptoms |  |  | 
| percentage of nocturnal awakenings due to asthma |  |  | 
| asthma symptom score |  |  | 
| number of inhalations of rescue medication |  |  | 
| proportion of patients with severe asthma exacerbations |  |  | 
| differences in morning PEF from diary |  |  | 
| differences in FEV1 and FVC from spirometry |  |  | 
| blood eosinophils |  |  | 
| AQLQ(S) |  |  | 
| health economic data |  |  | 
| vital signs |  |  | 
| laboratory work-up |  |  | 
| adverse events. |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Asthma, Ciclesonide, Fluticasone propionate, Salmeterol
Balanced Volume Replacement Therapy With Ringer's Acetate Solution in Burn Injury

Study Overview
=================
Brief Summary
-----------------
This observational study compares the influence of Ringer's Lactate solution and Ringer's Acetate solution on organ function scores following severe burn injury.

Detailed Description
-----------------
In the early period following severe burn injury volume replacement with high amounts of crystalloids is necessary. In this study we compare the organ function scores of a historical patient group, treated with Ringer's Lactate solution, with an actual patient population, treated with Ringer's Acetate solution.

Official Title
-----------------
Balanced Volume Replacement Therapy With Ringer's Acetate Solution in Burn Injury

Conditions
-----------------
Severe Burn Injury

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age >=18 years and <80years Burned surface area >20% and <70% Burn injury < 24 hours Agreement to the study procedures Exclusion Criteria: Burned surface area > 70% Expected survival time < 24 hours Acute or chronic heart failure NYHA III or IV Adult respiratory distress syndrome Renal failure Hepatic failure

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>Historical group: patients treated with Ringer's Lactate solution after severe burn injury | |
| 2<br>Actual group: patients treated with Ringer's Acetate solution after severe burn injury | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change of SOFA-score from day 3 to day 7 after severe burn injury |  | day3, day7, day28, day60 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes in electrolyte-balance |  | day3, day7, day28 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
burn injury, volume replacement, Ringer's Lactate solution, Ringer's Acetate solution, volume replacement with crystalloids